Pre-Made Efmarodocokin Alfa Biosimilar, Fusion Protein targeting IL22RA1/IL22R1 fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CRF2-9 for drug discovery and mechanism of action (MOA) research

Pre-Made Efmarodocokin Alfa Biosimilar, Fusion Protein targeting IL22RA1/IL22R1 fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CRF2-9 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Interleukin-22 (IL-22) is produced by various leukocytes, it preferentially targets cells with epithelial origins. IL-22 exerts essential roles in modulating various tissue epithelial functions, such as innate host defense against extracellular pathogens, barrier integrity, regeneration, and wound healing. Therefore, IL-22 is thought to have therapeutic potential in treating diseases associated with infection, tissue injury or chronic tissue damage. Efmarodocokin Alfa is an IL-22 recombinant fusion protein that links the human cytokine IL-22 with the Fc portion of a human immunoglobulin.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-821-1mg	1mg	3090
GMP-Bios-INN-821-10mg	10mg	Inquiry
GMP-Bios-INN-821-100mg	100mg	Inquiry
GMP-Bios-INN-821-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Efmarodocokin Alfa Biosimilar, Fusion Protein targeting IL22RA1/IL22R1 fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CRF2-9
INN Name	Efmarodocokin Alfa
Target	IL22RA1
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - IL22 (interleukin 22, IL-22, ILTIF, IL-TIF) - IGHG4 Fc (Fragment constant)
VD LC	Fusion - IL22 (interleukin 22, IL-22, ILTIF, IL-TIF) - IGHG4 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Genentech Inc. (S.San Francisco CA USA) Company
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0